United Kingdom· GB-APID-16591411000001103
Ilaris 150mg powder for solution for injection vials
A canakinumab product containing canakinumab, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Canakinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Canakinumab · ATC L04AC08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Canakinumab
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AC08
- ATC class
- Canakinumab
- Defined daily dose
- 2.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5010678909012
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
374 interactions on record for canakinumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Canakinumab · interactions on record
374 records
- 30 severe
- 337 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Canakinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumIlaris 150 mgNovartis Europharm
- CzechiaILARISNovartis Europharm Limited, Dublin
- SwedenIlaris 150 mg Pulver och vätska till injektionsvätska, lösningNovartis Europharm Limited
- SpainILARIS 150 mg POLVO PARA SOLUCION INYECTABLENovartis Europharm Limited
- IcelandIlarisNovartis Europharm Limited*
- PolandIlarisNovartis Europharm Limited
- FinlandIlarisNovartis Europharm Limited
- United StatesIlarisNovartis Pharmaceuticals Corporation
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ilaris
- Liechtenstein · Ilaris
- Norway · Ilaris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1b0f5346-03d5-4002-a6e5-8d40c3cfad35 GET /v1/drugs/1b0f5346-03d5-4002-a6e5-8d40c3cfad35?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "16591411000001103",
"desc": "Ilaris 150mg powder for solution for injection vials (Novartis Pharmaceuticals UK Ltd)",
"form": "Powder for solution for injection",
"vpid": "16592911000001100",
"source": "dmd",
"vtm_id": "775027002",
"strength": "150 mg",
"substance": "Canakinumab",
"ingredient": "Canakinumab",
"supplier_code": "2920101000001102"
}See everything about canakinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.